• Stempeutics signed a co-development agreement with Alkem
  for its stem cell therapy product Stempeucel® for treating Osteoarthritis of the knee
  
  
• Stempeutics signed a co-development agreement with Cipla
  for its stem cell therapy product Stempeucel® for treating Critical Limb Ischemia
  
  
• DCGI gives limited approval to market
  FIRST allogeneic cell therapy product in India
  
  
• Stempeutics Published CLI Phase 1
  (in Journal of Translational Medicine) and Phase 2 study (in Stem Cells Translational Medicine)outcomes
  
  
• Stempeutics Published OA Phase 2
  study outcomes (in Arthritis Research & Therapy)Stempeutics received Phase 4 PMS study approval for CLI due to Buerger's
  
  
• Stempeutics received Phase 3
  approval for CLI due to atherosclerosis
  
  
• Stempeutics received Form 28
  commercial manufacturing approval for its Manipal GMP facility
  
  
• Stempeutics receives Advanced Therapy Medicinal Product (ATMP)
  classification from European Medicines Agency (EMA) for its novel stem cell drug "Stempeucel^®"
  
  
• Stempeutics receives US process patent (8,956,862)
  for its novel stem cell drug "Stempeucel^®"
  
  
• Stempeutics gets stem cell patent in China
  (Chinese Application number: CN201080053627) for its novel stem cell drug "Stempeucel^®"
  
  
• Stempeutics published the novelty of Stempeutron medical device
  in the international journal "Stem Cells International"
  
  
• Stempeutics partners with Global Consortium of cell therapy companies seeking European Union funding to combat Coronavirus Infections in Europe.
  
  
• Stempeutics India signs an agreement with Novumcella Japan for development cooperation of Stempeucel® product for the Japanese market to treat Critical Limb Ischemia due to Buerger’s Disease.
  
  
• US patent office issued notification to grant Patent to Stempeutics for its innovative stem cell drug “Stempeucel” for treating Critical Limb Ischemia (CLI).
  
  
• CDSCO approves First “Made in India” novel Cell Therapy product “Stempeucel®” for commercial use for treating Critical Limb Ischemia.